| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5955757 | Chest | 2013 | 8 Pages |
Abstract
PcP can occur in association with rituximab, with the majority of cases having also received cytotoxic chemotherapy or significant doses of glucocorticoids. The clinical course of cases of PcP in patients treated with rituximab can be quite fulminant, with significant mortality. Primary prophylaxis should be considered in patients at risk, and secondary prophylaxis provided unless immune reconstitution is well assured.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Isabel MD, Eva M. MD, PhD, Ulrich MD, Andrew H. MD, FCCP,